Just because you ended up marrying a 400 pound dog (your sister) doesn't mean all woman are bad son. Grow up pal. Get a real life and a real job.
You discount the fact that agn been down 9 out of the last 11 days, but then bring up a 1 day event (endp) as an explanation of agn's ills??? I'd call you Chimp, were it not for the fact, that you're obviously much less intelligent than the average Monkey.
Shares of Allergan AGN are sharply lower today, weighed down by extremely negative sector-wide sentiment following a string of disappointing earnings reports by several peers. Notably, ENDP reported severely disappointing quarterly results and issued equally disappointing guidance Thursday night, sending shares 40% lower in today's session.
We believe investors are pointing to negative commentary on Endo's call (management noted challenging payer environment, increased generic competition, and weak pain market) as potential read-throughs for Allergan TEVA deal.
On our mid-April members-only webinar, we discussed Allergan's prospects at length, To quote directly from the call: "Is it tough to watch a stock that you know is going to go lower? Remember, the stock's at $219, probably goes to $200. We made no bones about that, but Pfizer's willing to pay $360 for a company that's [heading to] $200 … but understand there are some stocks in the world that it's going to take a couple of months." We also pointed to Allergan's May 10 earnings release as a very soft catalyst "but the real hard catalyst is when the Teva deal closes."
Being completely overlooked is a Reuters report last night that Teva is finalizing as much as $2 billion in asset-sale agreements to win U.S. antitrust clearance for its $40.5 billion acquisition of Allergan's generic drug portfolio, citing a source close to the matter. Teva has found buyers for nearly all the assets it expects to divest, including around 50 drugs already on the market and 25 in development that treat illnesses ranging from cancer to respiratory disease andcentral nervous system disorders. The source also indicated that Teva is still on track to close the deal in June.
While finalizing divestment plans does not guarantee FTC approval, the reports appear to validate Teva's commitment to closing the deal by any and every means possible. We view the reports as a positive development, and we continue to expect U.S. regulatcentral nervous system disorders. The source also indicated that Teva is still on track to close the deal in June.
While finalizing divestment plans does not guarantee FTC approval, the reports appear to validate Teva's commitment to closing the deal by any and every means possible. We view the reports as a positive development, and we continue to expect U.S. regulators to approve the transaction by the end of next month. As we've discussed in prior notes, Teva desperately needs the deal to close for purely economic reasons. First, and foremost, Teva needs Allergan's portfolio to gain the scale necessary to have a fighting chance of competing against industry juggernauts and the wave of reimbursement pressures. Second, if the deal fell through, Teva would have to swallow the $1 billion break-up fee.
The former is a far more important consideration, particularly in light of what we are witnessing today in respect to Endo Pharmaceuticals, a mid-cap generics manufacturer that lacks the scale to combat pricing and margin pressure. Scale and breadth are the two ingredients necessary to remain competitive in the generics industry. The only way Teva can obtain both is by pulling out all stops to ensure that its deal with Allergan goes through.
Closing the Teva deal is the most important upcoming catalyst for Allergan, as it will allow it to pay down its debt and open the balance sheet for further accretive capital returns (via buybacks and/or accretive acquisitions). We do understand official confirmation is necessary for the overhang to be removed, and would advise subscribers that shares could trade down to $180 in the near term. We reiterate our long-term conviction but reiterate that share appreciation will take time. As the company completes the Teva deal in late June and provides investors with incremental clarity and enhanced visibility, we expect investors to follow, albeit at a gradual pace.
We reiterate our $270 price target but recognize that the overhang clouding shares near-term will take time to clear.
Agn is trying to rid thmeselves of that division timmy!! Agn is a bloated pig with oodles of debt!!!! If agn is getting hit because of generics than the teva deal is not going through!!!
Nutcase on this board? Theya re on just every one however. What a friggin' loser. Generics starting with MCK have been really hit hard due to worries about price controls on these outrageous drug pricing frauds in America. Hopefully when Mrs C. gets in she'll drop the ball on the drug industry once and for all.
ALL generics have gotten taken to the woodshed because of further price controls. It's as simple as that chump.
The only targets that have been correct have been mine!! I have called thiswith 100% accuracy from the exact top and predicted every single move within pennies thereafter!!! My analysis is second to none!! Just read wha the market is telling you!! I called today"s action to perfection